Management of Obsessive-Compulsive Disorder (OCD)

Initial Treatment Selection

The American College of Psychiatry recommends cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) as the first-line treatment for OCD, with selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacotherapy, either alone or combined with CBT for more severe cases 1
CBT with ERP demonstrates superior efficacy compared to pharmacotherapy alone, with a number needed to treat of 3 for CBT versus 5 for SSRIs 1
ERP involves gradual and prolonged exposure to fear-provoking stimuli combined with instructions to abstain from compulsive behaviors, typically delivered over 10-20 sessions 2
Patient adherence to between-session homework (ERP exercises in the home environment) is the strongest predictor of both short-term and long-term treatment success 1, 2
Individual and group CBT delivered in-person or via internet-based protocols are all effective treatment modalities 1
SSRIs are first-line pharmacological treatment based on efficacy, tolerability, safety, and absence of abuse potential 1
Higher doses of SSRIs are required for OCD than for depression or other anxiety disorders 1
For severe OCD, combine CBT with SSRI treatment from the outset 1
Combined treatment is particularly beneficial for patients with severe symptoms, partial response to monotherapy, and significant comorbidities 1

Establish therapeutic alliance with patient and family members, explaining that OCD is a common disorder with available treatments that can achieve at least partial symptom reduction and improved quality of life 1
Address stigma, prejudice, and family accommodation behaviors that may maintain OCD symptoms 1
Explain the biological and psychological underpinnings of OCD and evidence-based treatment options 1
Administer SSRI treatment for a minimum of 8-12 weeks at maximum tolerated dose to assess efficacy 2
Long-term treatment is typically necessary as OCD is often a chronic condition 1
For CBT, monthly booster sessions for 3-6 months after initial treatment help maintain gains 1

Up to 50% of patients do not respond adequately to initial SSRI treatment, with SSRIs having a moderate effect size in OCD, and only one-third of patients with SSRI-resistant OCD showing clinically meaningful response to subsequent interventions 3
Add atypical antipsychotics to ongoing SSRI therapy for partial responders, with aripiprazole showing particular promise for augmentation 2, 3, 4
N-acetylcysteine has the largest evidence base among glutamatergic agents, with three out of five randomized controlled trials demonstrating superiority to placebo 3
Memantine augmentation can be considered, as several trials have demonstrated efficacy in SSRI augmentation for treatment-resistant OCD 3
Intensive CBT protocols (multiple sessions over a few days, sometimes in inpatient settings) may benefit treatment-resistant OCD 1
The FDA has approved deep repetitive transcranial magnetic stimulation (rTMS) for OCD treatment, with targets including the supplementary motor cortex, dorsolateral prefrontal cortex, medial prefrontal cortex, and anterior cingulate cortex 3
Deep brain stimulation (DBS) is reserved for very intractable cases (less than 1% of treatment-seeking individuals), with approximately 30-50% of patients with severe refractory OCD responding to treatment 3

Family involvement is crucial for children and adolescents with OCD 1
Computer-assisted self-help CBT interventions that include ERP components and last more than 4 weeks can be effective alternatives when in-person therapy is not available 1
Treatment should address any comorbid conditions, which may require additional interventions beyond standard OCD treatment 1
Comorbid depression should be addressed aggressively, as depressive symptoms mediate the relationship between OCD and impaired quality of life 2, 4

Do not use inadequate SSRI doses or insufficient treatment duration before declaring treatment failure 1
Do not ignore family accommodation behaviors that maintain OCD symptoms 1
Do not overlook the importance of between-session ERP homework, as adherence is the strongest predictor of outcomes 1, 2
Recognize that OCD is frequently misunderstood by both clinicians and patients, emphasizing the need for specialized education 1
Monitor ongoing risk-benefit ratio in patients receiving antipsychotic augmentation, with particular attention to metabolic adverse events 3

Periodically reassess the need for continued treatment, though most patients require ongoing therapy to prevent relapse 1
Maintenance therapy is often needed for 12-24 months or longer 2, 4
Regular evaluation of quality of life is essential, as OCD significantly reduces quality of life across all domains including work, family, and social activities 3, 4